by Clinical Neuropsychologist | Monday, December 23, 2024 | Dementia
Abstract The Alzheimer’s Disease Neuroimaging Initiative (ADNI) Private Partners Scientific Board (PPSB) Diversity, Equity, and Inclusion Working Group (DE&I WG) was established to work with the ADNI3 Diversity Task Force to provide an industry perspective...
by Clinical Neuropsychologist | Friday, December 20, 2024 | Dementia
Abstract INTRODUCTION This study investigated the associations of brain age gap (BAG)—a biological marker of brain resilience—with life exposures, neuroimaging measures, biological processes, and cognitive function. METHODS We derived BAG by subtracting predicted...
by Clinical Neuropsychologist | Thursday, December 19, 2024 | Dementia
Abstract INTRODUCTION While there may be microbial contributions to Alzheimer’s disease (AD), findings have been inconclusive. We recently reported an AD-associated CD83(+) microglia subtype associated with increased immunoglobulin G4 (IgG4) in the transverse...
by Clinical Neuropsychologist | Thursday, December 19, 2024 | Dementia
Abstract INTRODUCTION Cerebrovascular dysfunction occurs in Alzheimer’s disease (AD), impairing hemodynamic regulation. Large conductance Ca2+-activated K+ channels (BKCa) regulate cerebrovascular reactivity and are impaired in AD. BKCa activity depends on...
by Clinical Neuropsychologist | Thursday, December 19, 2024 | Dementia
Abstract To understand the potential benefits of emerging Alzheimer’s disease (AD) therapies within and beyond clinical trial settings, there is a need to advance current outcome measurements into meaningful information relevant to all stakeholders. The...
by Clinical Neuropsychologist | Wednesday, December 18, 2024 | Dementia
Abstract The immune system is a key player in the onset and progression of neurodegenerative disorders. While brain resident immune cell-mediated neuroinflammation and peripheral immune cell (eg, T cell) infiltration into the brain have been shown to significantly...
